SOCRA CCRP Documentation 2 — Questions and Answers
Question 1: What is the primary purpose of maintaining a Trial Master File (TMF) in a clinical trial?
- To store investigator CVs only
- To provide documented evidence of trial conduct and regulatory compliance (Correct answer)
- To track patient enrollment numbers
- To manage the study budget
Correct answer: To provide documented evidence of trial conduct and regulatory compliance
The TMF serves as the definitive collection of essential documents that provides documented evidence that the clinical trial was conducted in accordance with GCP, applicable regulations, and the protocol.
According to ICH-GCP E6(R2) Section 8, the Trial Master File is established at the beginning of a trial and should be maintained throughout the trial's duration. It contains all essential documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate compliance with standards of GCP and all applicable regulatory requirements. During regulatory inspections, the TMF is typically the first set of documents reviewed. A well-organized TMF facilitates trial management, audits, and inspections.
Question 2: How long must essential clinical trial documents typically be retained after the formal discontinuation of a drug's clinical development?
- 1 year
- At least 2 years (Correct answer)
- At least 5 years
- At least 15 years
Correct answer: At least 2 years
ICH-GCP guidelines state that essential documents should be retained for at least 2 years after the last approval of a marketing application or after formal discontinuation of clinical development of the investigational product.
ICH-GCP E6(R2) Section 4.9.5 and 5.5.12 specify document retention requirements. The sponsor should retain sponsor-specific essential documents for at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications, or at least 2 years have elapsed since the formal discontinuation of clinical development. However, local regulations may require longer retention periods, and some countries mandate retention for 15 years or more. The investigator should follow the longer of the applicable requirements.
Question 3: Which document must be signed before a sponsor can ship investigational product to a clinical trial site?
- Site budget agreement
- Clinical Trial Agreement (CTA) and regulatory approval (Correct answer)
- Informed consent form only
- Data management plan
Correct answer: Clinical Trial Agreement (CTA) and regulatory approval
Before investigational product can be shipped to a site, both a Clinical Trial Agreement and the appropriate regulatory approval (such as IRB/IEC approval and regulatory authority authorization) must be in place.
The Clinical Trial Agreement (CTA) is a legally binding contract between the sponsor and the investigator/institution that outlines the responsibilities, obligations, and financial arrangements for the conduct of the trial. Regulatory approval from the relevant health authority and IRB/IEC approval must also be obtained. Without these documents, shipping investigational product to a site would violate GCP requirements and potentially local laws. The CTA typically addresses liability, insurance, publication rights, and intellectual property in addition to operational matters.
Question 4: What is a source document in the context of clinical trial documentation?
- A copy of the case report form
- An original document, data, or record where clinical findings are first recorded (Correct answer)
- The study protocol
- The statistical analysis plan
Correct answer: An original document, data, or record where clinical findings are first recorded
Source documents are original documents, data, and records where clinical findings, observations, or other activities in a clinical trial are first recorded. They include hospital records, clinic charts, laboratory notes, and subject diaries.
ICH-GCP defines source documents as original documents, data, and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified as accurate, microfiches, photographic negatives, microfilm or magnetic media, X-rays, subject files). Source data is all information in original records and certified copies of original records. The principle of source data verification (SDV) requires that CRF entries can be traced back to these original source documents to verify accuracy and completeness.
Question 5: Which section of the Investigator's Brochure (IB) contains information about the known and potential risks of the investigational product?
- Summary of Data and Guidance for the Investigator (Correct answer)
- Physical, Chemical, and Pharmaceutical Properties
- Introduction
- Table of Contents
Correct answer: Summary of Data and Guidance for the Investigator
The Summary of Data and Guidance for the Investigator section provides an overall discussion of nonclinical and clinical data, including known and potential risks and anticipated adverse events to help the investigator manage subjects appropriately.
The Investigator's Brochure is structured according to ICH-GCP Section 7 and includes: Title Page, Confidentiality Statement, Table of Contents, Summary, Introduction, Physical/Chemical/Pharmaceutical Properties, Nonclinical Studies, Effects in Humans, and Summary of Data and Guidance for the Investigator. This final summary section is critical because it integrates all available data to provide the investigator with a clear understanding of potential risks, precautions, and special monitoring requirements. It is updated at least annually and whenever significant new information becomes available.
Question 6: What is the purpose of a delegation log in a clinical trial?
- To record all protocol amendments
- To document the study staff authorized to perform specific trial-related duties (Correct answer)
- To track monitoring visit dates
- To list all regulatory submissions
Correct answer: To document the study staff authorized to perform specific trial-related duties
The delegation log (also called the delegation of authority log) identifies all persons authorized by the principal investigator to perform significant trial-related duties and specifies those duties.
According to ICH-GCP Section 4.1.5, the investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties. The delegation log typically includes the staff member's name, signature, initials, role, specific delegated tasks, training documentation reference, and the dates the delegation is effective. This document is essential for demonstrating that all trial activities were performed by qualified, authorized personnel and is a key document reviewed during monitoring visits and regulatory inspections. Any changes in delegation must be documented promptly.
SOCRA CCRP Documentation 2
What is the primary purpose of maintaining a Trial Master File (TMF) in a clinical trial?